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Abstract
Purpose Prediction of mortality risk is important in the man-
agement of chronic heart failure (CHF). The aim of this study
was to create a prediction model for 5-year cardiac death
including assessment of cardiac sympathetic innervation using
data from a multicenter cohort study in Japan.
Methods The original pooled database consisted of cohort
studies from six sites in Japan. A total of 933 CHF patients
who underwent 123I-metaiodobenzylguanidine (MIBG) imag-
ing and whose 5-year outcomes were known were selected
from this database. The late MIBG heart-to-mediastinum ratio
(HMR) was used for quantification of cardiac uptake. Cox
proportional hazard and logistic regression analyses were used
to select appropriate variables for predicting 5-year cardiac
mortality. The formula for predicting 5-year mortality was
created using a logistic regression model.
Results During the 5-year follow-up, 205 patients (22 %) died
of a cardiac event including heart failure death, sudden cardiac
death and fatal acute myocardial infarction (64 %, 30 % and
6 %, respectively). Multivariate logistic analysis selected four
parameters, including New York Heart Association (NYHA)
functional class, age, gender and left ventricular ejection frac-
tion, without HMR (model 1) and five parameters with the
addition of HMR (model 2). The net reclassification improve-
ment analysis for all subjects was 13.8 % (p<0.0001) by
including HMR and its inclusion was most effective in the
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downward reclassification of low-risk patients. Nomograms
for predicting 5-year cardiac mortality were created from the
five-parameter regression model.
Conclusion Cardiac MIBG imaging had a significant additive
value for predicting cardiac mortality. The prediction formula
and nomograms can be used for risk stratifying in patients
with CHF.
Keywords Chronic heart failure .
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Introduction
Chronic heart failure (CHF) remains a major cause of death in
current medical practice. Improving survival while maintain-
ing good quality of life is an important goal for the medical
community. With respect to diagnostic tools for assessing
cardiac status, a number of clinical examinations and bio-
chemical tests can provide information on the functional status
of patients with CHF [1]. In addition to effective drug inter-
ventions using beta-blockers and/or renin-angiotensin-
aldosterone inhibitors, nonpharmacological interventions
have been shown to significantly reduce cardiac mortality
[2]. However, due to the high cost of many such interventions,
particularly the use of implanted devices, these recent ad-
vances have increased the importance of appropriate identifi-
cation of patients at high-risk of lethal events.
Among the various cardiac imaging modalities, 123I-
metaiodobenzylguanidine (MIBG) imaging has the unique
feature of visualizing sympathetic nervous function. MIBG
shares pathways with noradrenaline for uptake, storage and
release in sympathetic nerve endings [3]. Hyperactivity of
sympathetic nerve function results in decreased cardiacMIBG
uptake, a finding associated with an increased occurrence of
unfavorable cardiac events including pump failure and lethal
cardiac arrhythmias [4–6]. Both prospective studies and meta-
analyses have shown that MIBG imaging results can be used
to predict fatal cardiac events and serious arrhythmias [7–9].
Despite its documented prognostic power [10], MIBG
imaging is under-utilized in clinical practice, primarily be-
cause the benefit of this procedure in addition to conventional
clinical parameters including heart failure symptoms, left ven-
tricular function and biochemical data is not clearly defined.
However, several recent analyses have shown that MIBG
results provide additional prognostic value to the validated
multivariable Seattle Heart Failure model [11, 12]. We have
compiled a pooled MIBG cohort database based on studies
performed at six Japanese institutions with follow-up of up to
15 years [13]. Our analyses confirmed that MIBG is a potent
predictor of all-cause death.
This study focused on cardiac death and in particular the
prediction of fatal cardiac events by adding information from
MIBG imaging. The aims of this study were to analyze factors
for predicting cardiac death and to create a prediction model




Individual datasets from six prospective MIBG cohort studies
performed in Japan between 1990 and 2009 were combined to
make a pooled database of 1,322 CHF patients as previously
reported [5, 13–19]. All patients were enrolled in prospective
observational studies, following which MIBG was approved
for clinical use in Japan. The diagnosis of CHF was
established by cardiologists in each hospital using standard
Framingham diagnostic criteria. All the original cohort studies
conformed with the principles outlined in the Declaration of
Helsinki (Br Med J 1964;2:177). All the studies were ap-
proved by the ethics committee or institutional review board
in each hospital, and informed consent was obtained from the
patients.
To create a single pooled database, cardiology specialists
and/or nuclear medicine specialists in six hospitals created
databases including common clinical parameters and updated
the outcome in some institutions. For this study, only patients
with known 5-year outcomes were included (933 patients).
The demographics of this population are summarized in
Table 1. The underlying diseases were dilated cardiomyopa-
thy (42.6 %), ischemic heart disease (26.3 %), and miscella-
neous causes of heart failure (31.1 %) including arrhythmia,
hypertrophic cardiomyopathy, secondary cardiomyopathies
(diabetes, hypertension, collagen diseases, etc.), valvular heart
diseases, myocarditis and cardiac sarcoidosis. Eleven patients
(1.2 %) had implantable cardioverter-defibrillators (ICD) and
7 (0.8 %) had cardiac resynchronization therapy (CRT).
123I-MIBG study
Anterior planar images using scinticameras equipped with
low-energy type collimators were obtained at 15 – 30 min
(early phase) and 3 – 4 h (late phase) after injection of
111 MBq 123I-MIBG (Fujifilm RI Pharma Co. Ltd., Tokyo,
Japan) in all institutions. To calculate a heart-to-mediastinum
ratio (HMR), a whole-heart region and a mediastinal rectan-
gular region in the upper mediastinum were drawn. Although
both early and late HMRs were calculated in each institution,
we used the late HMR for creating the prediction model, since
late HMR showed better diagnostic accuracy than early HMR
[13]. The mean late HMR was 1.71±0.33.
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Left ventricular function
Left ventricular ejection fraction (LVEF) was determined
using a gated blood-pool study (317 patients, 34 %), two-
dimensional echocardiography (498 patients, 54 %), gated
SPECT (98 patients, 11 %) and either a gated blood-pool
study or echocardiography (18 patients, 2 %). The mean
LVEF was 35.7±13.1 % (Table 1).
Outcome
Five-year cardiac death, including heart failure death, sudden
cardiac death (witnessed cardiac arrest and death within 1 h of
onset of acute symptoms or unexpected death in patients
known to have been well within the previous 24 h), and fatal
acute myocardial infarction, was determined by the original
study investigators. While clinical outcomes were confirmed
from patient medical records or telephone interview in each
institution, only definitely confirmed cardiac death was
considered as an event. Noncardiac death was dealt with as
censored at the time of death.
Statistical analysis
All the clinical information and MIBG results were sent to a
central institution (Kanazawa University), and were indepen-
dently analyzed. Data are expressed as means ± standard
deviation (SD). Contingency table analysis was examined
using likelihood ratio and Pearson statistics.
Variables included in the multivariate analyses were age,
gender, early HMR, late HMR, MIBG washout rate, NYHA
functional class, LVEF, history of diabetes, hypertension,
dyslipidemia, atrial fibrillation and sustained ventricular
tachycardia, and medications (including beta blockers, di-
uretics, angiotensin-converting enzyme inhibitors, angioten-
sin receptor blockers and aldosterone antagonists). B-type
natriuretic peptide (BNP) was not used in the final analysis
because of the limited number of patients available for anal-
ysis (299 patients). Variables derived from electrocardiogra-
phy were not included in the assembled dataset.
Multivariate Cox proportional hazard analysis was per-
formed. Logistic regression analysis was used for single
HMR and multiple variables, and receiver operating charac-
teristic (ROC) curves and areas under the curves (AUC) were
calculated. To create a prediction model, logistic models with
single or multiple variables were used to calculate the cardiac
mortality. Inverse prediction of HMR was also performed
based on the prediction models to evaluate the threshold for
low risk of mortality. Net reclassification improvement (NRI)
analysis was based on the prediction models with and without
HMR. The 5-year risk levels were defined as low (<5 %),
intermediate (5 – 25 %) and high (>25 %). The threshold of
5 % corresponded to an accepted low-risk threshold of 1 %
mortality per year. The threshold for high-risk (25 %; 5 % per
year) was chosen to exceed the approximately 4 % per year
cardiac death rate in the total population. A p value <0.05 was
considered significant. Statistical analysis was performed
using JMP 10.0.2 software (SAS Institute Inc., Cary, NC),
and mathematical calculation and software for creating




A total of 205 patients (22.0 %) died of a cardiac event,
including 132 (14.1 %) with heart failure death, 61 (6.5 %)
with sudden cardiac death and 12 (1.3 %) with fatal acute
myocardial infarction. Five-year cardiac death rates for
NYHA classes I to IV were 20 of 221 (9.1 %), 53 of 391
Table 1 Demographics of the 933 patients
Characteristic Value
Age (years), mean ± SD 60.8±13.5
Male gender (%) 71 .0





LVEF (%), mean ± SD 35.7±13.1
123I-MIBG HMR, mean ± SD
Early 1.86±0.39
Late 1.71±0.33
Time of follow-up to event (years), mean ± SD 7.7±4.3
BNPa (pg/ml), mean ± SD 405±451
Ischemic heart disease (%) 26.3 %







Angiotensin converting enzyme inhibitor 41.1
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(13.6 %), 100 of 257 (38.9 %) and 32 of 63 (50.8 %), respec-
tively (χ2=111.3, p<0.0001, Pearson's analysis). For the fol-
lowing analysis, NYHA functional class was classified into
two groups: NYHA classes I/II and III/IV (cardiac death
11.9 % and 41.3 %, respectively; χ2=105.3, p<0.0001,
Pearson's analysis). Five-year death rates in patients with
and without ischemic heart disease were 50 of 245 (20.4 %)
and 155 of 688 (22.5 %), respectively (not significantly dif-
ferent). However, causes of cardiac death differed between the
ischemic and nonischemic patients. In the former group, only
40 % of deaths were due to progressive heart failure, com-
pared with 72 % in the latter group (p<0.0001; Fig. 1). Con-
versely, the incidence of sudden cardiac death and fatal acute
myocardial infarction was higher in the ischemic group than in
the nonischemic group.
Univariate logistic regression analysis with HMR
A univariate logistic model using HMRwas applied to patient
groups with NYHA classes I/II and III/IV, and ROC analysis
was performed. In patients with NYHA functional classes I/II,
parameter estimates of HMR showedχ2=36.6 and a unit odds
ratio (OR) of 0.063; the ROC AUC was 0.717 (p<0.0001). In
patients with NYHA classes III/IV, parameter estimates of
HMR showed χ2=11.6 and a unit OR of 0.251; the ROC
AUC was 0.609 (p=0.0007).
Proportional hazard analysis
Cox proportional hazard analysis was performed using the
variables listed in Table 1. In the multivariate proportional
hazard analysis NYHA functional class, late HMR, age, gen-
der and LVEF were significant variables for predicting 5-year
cardiac mortality (Table 2).
Five-year logistic regression analysis
In the multivariate logistic regression analysis without HMR
significant variables were NYHA functional class (OR 4.3,
χ2=66.7, p<0.0001), age (OR 1.02, χ2=11.6, p=0.0007),
LVEF (OR 0.98, χ2=11.3, p=0.0008) and male gender (OR
1.8, χ2=7.9, p=0.0049). The ROC AUC was 0.749 (95 %
confidence interval, CI, 0.709 – 0.785). In the logistic regres-
sion analysis with HMR significant variables were NYHA
functional class (OR 3.7, χ2=51.4, p<0.0001), HMR (OR
0.15, χ2=31.5, p<0.0001), age (OR 1.03, χ2=11.9, p=
0.0006), male gender (OR 1.7, χ2=6.5, p=0.011) and LVEF
(OR 0.98, χ2=5.1, p=0.024). The ROC AUC was 0.780
(95 % CI 0.744 – 0.813). Of the two ROC curves, the model
including HMR had a significantly larger AUC (p=0.0015).
Reclassification improvement analysis
The NRI analysis was performed using the four-parameter
logistic model created by the combination of NYHA func-
tional class, age, gender and LVEF (model 1) and by the five-
parameter model that included late HMR (model 2; Table 3).
Of the 205 patients who died of a cardiac event, classification
was improved in 23 and made worse in 13 using the five-
parameter model. The net gain in reclassification proportion
(Table 4) was 4.9 % (p=0.096). Of the 725 patients who did
not die of a cardiac event, 38were reclassified upward and 103
Fig. 1 Cardiac death in the
ischemic (a) and nonischemic (b)
groups. The cause of death is
further classified into sudden
cardiac death, heart failure death
and fatal acute myocardial
infarction (AMI). A significant
difference was observed in the
breakdown of the causes of
cardiac death between the
ischemic and nonischemic groups
(Pearson χ2=26.1, p<0.0001)
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downward, with a net gain in reclassification of −9.0 %
(p<0.0001). The NRI in all subjects was 13.8 % (p<0.0001).
Thus, model 2 significantly improved the identification of
patients at low risk of cardiac death when compared to model 1.
Prediction of cardiac death using the logistic model
Based on the 5-year logistic regression analysis, mortality
rates were estimated using the formula with the five variables
(model 2):
f NYHA functional class; age; gender;HMR;LVEFð Þ ¼
1=ð1þ Exp½−ðbintercept þ bnyha*NYHA Classþ bage  age
þ bgender  gender þ bef  EF %ð Þþ bhmr  HMRÞÞ
 100 asterisk denotes multiplicationð Þ;
where the variables bintercept, bnyha, bage, bgender, bef and bhmr
were derived from the parameter estimates of the model and
were 0.178, 1.297 (χ2=51.4, p<0.0001), 0.025 (χ2=11.9, p=
0.001), 0.262 (χ2=6.5, p=0.011), −0.017 (χ2=5.1, p=0.024)
and −1.882 (χ2=31.5, p<0.0001) respectively. In this formu-
la, NYHA functional class (class I/II, 0; class III/IV, 1) and
gender (female, 0; male, 1) were categorical variables, and
age, LVEF and HMR were continuous variables.
Representative graphs for 60-year-old patients are shown in
Fig. 2. The 5-year mortality rate can also be calculated from
the risk calculation formula as shown in Fig. 3.
Prediction of low-risk for cardiac mortality
To identify the patients at low risk of cardiac mortality (<5 %/
5 years), inverse prediction was performed using the logistic
model and a single HMR variable in patients with NYHA
classes I/II. Based on the plots of mortality risk versus HMR,
patients with NYHA classes III/IV were excluded, since 5 %
risk per 5 years was not expected to be associated with HMR
in the clinical range. The predicted HMR in patients with a
5 % probability of cardiac death in 5 years was 2.02 (95 % CI
1.88 – 2.27). In patients aged ≥65 years and <65 years, the
predicted HMR was 2.01 (95 % CI 1.86 – 2.34) and 2.00
(95 % CI 1.79 – 2.67), respectively (Fig. 4a). In patients with
LVEF >35 % and ≤35 %, the predicted HMR was 1.95 (95 %
CI 1.79 – 2.32) and 2.14 (95 % CI 1.90 – 2.89), respectively
(Fig. 4b).
Discussion
In this study MIBG HMR was a strong predictor of 5-year
cardiac mortality in CHF patients. The ROC and NRI analyses
showed additional value of MIBG over conventional clinical
parameters. In the logistic regression models the variables age,
gender, NYHA functional class, LVEF and MIBG HMR were
significant predictors of cardiac death. The contribution of
MIBG was particularly significant in reclassifying patients as
lower risk. In CHF patients with NYHA class I/II the HMRwas
2.0 (associated with a cardiac death rate of 5 % in 5 years).
Table 2 Cox proportional hazard
analysis for 5-year cardiac death Variable Hazard ratio Lower 95 % Upper 95 % Reciprocal of hazard ratio p value
Age 1.024 1.013 1.035 0.977 <0.0001
NYHA I/II vs. III/IV 2.574 1.980 3.359 0.388 <0.0001
Late HMR 0.246 0.156 0.386 4.064 <0.0001
Male gender 1.524 1.146 2.054 0.656 0.0035
LVEF 0.982 0.970 0.993 1.019 0.0035
Table 3 Reclassification analysis in patients who did and did not die of a
cardiac event
NYHA class+age+gender+LVEF NYHA class+age+gender+LVEF+HMR
<5 % 5 – 25 % >25 %
Subjects who died
<5 % 0 2 0
5 – 25 % 4 52 21
>25 % 0 9 117
Subjects who survived
<5 % 35 7 0
5 – 25 % 72 405 31
>25 % 2 29 144
Table 4 Net reclassification in patients who did and did not die of a
cardiac event
Improved Made worse Same NRI (%) p value
Subjects who died 23 13 169 4.9 0.096
Subjects who
survived
103 38 584 9.0 <0.0001
Entire population 13.8 <0.0001
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Accepted prognostic markers for CHF patients include
NYHA functional class, LVEF, BNP levels, and
electrocardiographic indices such as QRS duration [10, 20].
The present analysis using pooled data from several
Fig. 2 Five-year cardiac mortality based on the five-parameter logistic
model. Nomograms for age 60 years are shown for each gender. The
nomogram curves are plotted for ejection fractions of 20 %, 35 %, 50 %
and 65 % in patients with NYHA classes I/II and III/IV. To use these
nomograms, a chart of corresponding age, NYHA class and gender is
selected, and the cross-over point of the curves with LVEF and HMR is
determined
Fig. 3 Risk calculation based on
five variables. Regions of interest
on heart and mediastinum are
shown. a In a 65-year old female
patient with NYHA class II and
LVEF 25 %, HMR was 2.3, and
the mortality risk could be
calculated as 4.9 %/5 years. b A
67-year old male patient with
NYHA class I and EF 45 %
showed HMR of 1.1, and
calculated mortality risk was
32 %/5 years. Each prediction
curve is drawn as a function of
HMR based on the multiple
logistic models of 5 parameters.
During the follow-up, the first
patient was alive for 5 years, and
the second patient died from
pump failure in 2.6 years after
MIBG study
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prospective cohort studies showed that assessment of cardiac
sympathetic innervation using MIBG had independent and
additive value for estimating the risk of a fatal cardiac event
in a wide range of CHF patients over a long follow-up period.
As patient-level data were used in the analyses, the results do
not have many of the limitations of those from single-center
studies or standard meta-analyses based on published data.
The significant number of patients and the long follow-up also
contribute to the quality of the combined results. This was
made possible by the fact that MIBG has been used in the
Japanese healthcare system and reimbursed by health insurers
since 1992, allowing accumulation of ample experience with
the use of MIBG imaging in CHF [9, 13]. This background in
Japan thus enabled the creation of prediction models over the
long term in CHF patients in the present study.
Based on the proportional hazard and logistic regression
analyses, five parameters (NYHA functional class, age, gen-
der, LVEF and HMR) were selected for the prediction model.
Of these parameters, dichotomous NYHA functional class
showed the highest OR and χ2 value, which might be antic-
ipated given the substantially poorer prognosis in CHF
patients with NYHA classes III and IV. Inclusion of HMR
reduced the prognostic contribution of LVEF to the model,
consistent with the results for all-cause death in the full pop-
ulation, where MIBG showed better discrimination between
high-risk and low-risk CHF patients than LVEF [13]. This
result may correspond to previous findings that there is a non-
negligible fraction of high-risk heart failure patients with
preserved LVEF and that cardiac MIBG assessment can iden-
tify these high-risk patients with preserved LVEF [21].
Clinically useful diagnostic tools which may aid therapeu-
tic decisions have been developed, and several have examined
the additive value ofMIBG imaging. The Seattle Heart Failure
Model is one of the validated prediction models for estimating
mortality risk [10, 20]. This model, which includes commonly
obtained clinical data such as age, gender, NYHA functional
class, medication, and laboratory values including sodium,
hemoglobin and cholesterol, has been shown to be improved
by addition of HMR [11]. In one small study, a multivariate
Cox analysis revealed that the MIBG washout rate and Seattle
Heart Failure Model score were independent predictors of
cardiac death. A subanalysis of patients in the ADMIRE-HF
trial also showed that the addition of MIBG imaging to the
Seattle Heart Failure Model improved risk stratification [12].
Thus, further study is warranted to examine the performance
of the present proposed model in conjunction with a validated
clinical model, as the performance of a combined assessment
might surpass that of either model individually.
In contrast to the Seattle Heart Failure Model, which in-
cluded more than 15 variables, a simpler model using a
smaller number of readily available clinical variables and
MIBG might be more convenient for clinicians involved in
the management of CHF patients. An advantage of our five-
variable model is that LVEF and MIBG parameters are avail-
able from current quantitative software and can be incorporat-
ed into a final computer output.
Although data from follow-up of nearly 15 years were
available in some patients in the original database, the ratio-
nale for selecting the 5-year mortality analysis was that this
time frame is relevant to the use of most current therapeutic
approaches in CHF patients. Risk estimation over 5 years
represented a compromise in terms of practical clinical signif-
icance, since outcomes during longer follow-up can be affect-
ed by many factors, including changes in medication, comor-
bidities and progression of disease. This type of prediction
model has been presented using myocardial perfusion imag-
ing but not previously with MIBG studies, and could facilitate
more effective use of the test to understand the risk of future
events [22, 23]. The present model and nomograms could
provide more precise risk stratification and thereby contribute
to appropriate selection of therapeutic strategies in CHF
patients.
Estimation of mortality risk in patients with CHF could
provide a more rational and cost-effective basis for decisions
Fig. 4 Inverse prediction of 5-year mortality using the logistic model
with HMR for patients aged ≥65 years and <65 years with NYHA
functional classes I and II
Eur J Nucl Med Mol Imaging (2014) 41:1673–1682 1679
on specific medications and cardiac devices. In particular,
identifying low-risk patients would have immediate practical
value. For example, in patients with a prior myocardial infarc-
tion who might be at high risk of ventricular tachyarrhythmia,
the use of prophylactic therapy with an ICD to improve
survival [24] might be less desirable if a low long-term mor-
tality risk is demonstrated. In this study, patients with NYHA
class I and II and HMR >2.0 had a low risk of cardiac
mortality (<5%/5 years), suggesting primary prevention ICDs
might not be necessary in such individuals. Instead, optimal
medical therapy might be more appropriate in this population.
On the other hand, higher risk patients could be treated using
more aggressive medical treatment with ICD and a CRT-
defibrillator as judged appropriate. Our previous studies have
suggested the efficacy of cardiac MIBG imaging for appro-
priate ICD indications or for predicting the need for ICD use
[25, 26]. The present risk calculations could thus be used in
conjunction with developing therapeutic strategies.
As noted previously, the present study showed that the
HMR as more useful for reclassifying downward into low-
risk groups, opposite to the finding in the ADMIRE-HF
subanalysis using the Seattle Heart Failure Model. One pos-
sible reason for this difference is the difference in patient
populations, with the present analyses including patients with
NYHA classes I to IV with average LVEF of 36 %, while the
ADMIRE-HF study included only those with NYHA classes
II and III with average LVEF of 27%. The mean HMRs in the
two studies were 1.71 and 1.44, respectively, suggesting
worse functional status in the ADMIRE-HF study. However,
this difference could merely reflect technical differences be-
tween imaging equipment in Japan versus gamma cameras in
the US and Europe. Another potential explanation is the
substantially higher prevalence of patients with non-
ischemic HF in the Japanese patients (74 %) versus the
ADMIRE-HF patients (34 %) and the lower overall mortality
in the Japanese HF patients. However, these observations
suggest that MIBG imaging might be more effective in
reclassifying upward to a higher risk cohort (such as
ADMIRE-HF) and downward to a lower risk population such
as that examined in this study.
Limitations
Since many patients imaged in the 1990s were included in the
present study, BNP was not available for all patients, and it
could not be included in the model. However, while single
BNP measurements often depend on noncardiac factors such
as patient condition and medical treatment, HMR using car-
diac MIBG activity is relatively stable and may be more
appropriate as a baseline assessment for long-term risk. The
present prediction model reflects the derivation cohort, and
when applied to other CHF populations, the optimal thresh-
olds of HMR may differ. However, in recent reviews and
multicenter studies, the HMR thresholds for low-risk patients
have been between 1.6 and 1.8, similar to the findings pre-
sented here [7–9]. HMR can also vary depending on the types
of camera–collimator combinations used, and although it is
possible to normalize these results using suitable calibration
techniques [27], such standardization was not possible in the
present study. Unlike prospective studies in which complete
laboratory and ECG data are available for every patient, such
data were not available in this study, potentially limiting the
scope of the derived model. Validation studies using this
MIBG model will be important for advancing its use in
clinical patients. There were a greater number of patients with
nonischemic heart disease in this Japanese cohort compared
with American/European cohorts in other studies of CHF
patients [7, 28]. The present study, however, showed compa-
rable cardiac mortality in ischemic and nonischemic CHF
groups. Therefore, this prediction model should be valid for
both groups, although the ischemic group showed a higher
incidence of fatal acute myocardial infarction and sudden
cardiac death, whereas the nonischemic group showed a
higher incidence of pump failure death.
The rates of use of standard CHF medications such as beta
blockers, angiotensin-converting enzyme inhibitors and an-
giotensin receptor blockers and aldosterone inhibitors were
lower (30 – 70 %) than in contemporary CHF studies, but
these variables were nevertheless not significant in the multi-
variate analysis. Considering that the earliest patients in the
study were examined prior to routine use of many of these
medications in CHF patients and that multiple medication
changes might have occurred during long-term follow-up,
the relevance of this observation is uncertain. Information on
other cardiac medications, such as diuretics and those used to
treat arrhythmias, such as amiodarone, was also not included
in the database. Of note, the associated conditions of diabetes,
dyslipidemia and hypertension were not predictors of cardiac
death in the study population.
Conclusion
The present study confirmed the long-term prognostic value
of MIBG imaging in CHF patients and supported develop-
ment of a potentially useful five-variable prediction model for
cardiac death. The prediction model can be used as the basis
for graphical nomograms or computer applications to assist
clinicians in stratifying risk in their CHF patients. With further
validation, these methods could contribute to improvements in
the quality and cost-effectiveness of CHF patient care.
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